NAT10 and gastric cancer: To further evaluate whether glucose deficiency or autophagy activation inhibits GC progression by downregulating NAT10, we further constructed a subcutaneous xenograft model using GC cells overexpressing NAT10 and corresponding control cells, and treated these mice with 2-DG or rapamycin.